Paratek Pharmaceuticals Inc. (PRTK)

The total asset value of Paratek Pharmaceuticals Inc. (PRTK) stood at $ 348 Mln as on 30-Jun-23

The share price of Paratek Pharmaceuticals Inc. (PRTK) is $2.230000 (NASDAQ) as of 21-Sep-2023 09:30 EDT. Paratek Pharmaceuticals Inc. (PRTK) has given a return of -30.66% in the last 3 years.

Paratek Pharmaceuticals Inc. (PRTK) has a market capitalisation of $ 128 Mln as on 21-Sep-2023. As per Value Research classification, it is a Small Cap company.

The P/B ratio of Paratek Pharmaceuticals Inc. (PRTK) is 0.00 times as on 21-Sep-2023, a -1% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of Paratek Pharmaceuticals Inc. (PRTK) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Paratek Pharmaceuticals Inc. (PRTK) and enter the required number of quantities and click on buy to purchase the shares of Paratek Pharmaceuticals Inc. (PRTK).

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

The CEO & director of Mr. Michael F. Bigham CPA, CPA, M.B.A., MBA. is Paratek Pharmaceuticals Inc. (PRTK), and CFO & Sr. VP is Dr. Evan Loh FACC, FAHA, M.D..

The promoters of Paratek Pharmaceuticals Inc. (PRTK) have pledged 0% of the total equity as on Jun-23.

Some of the close peers are:

No, TTM profit after tax of Paratek Pharmaceuticals Inc. (PRTK) was $-63 Mln.